Heparina Sódica B Braun (Heparin Sodium)

Heparina Sódica B Braun is indicated for clinical situations where anticoagulation is required to prevent or treat abnormal clot formation.

• Prevention of venous thromboembolism in surgical or immobilized patients.
• Treatment of acute deep vein thrombosis and pulmonary embolism.
• Anticoagulation during cardiac surgery or extracorporeal circulation.
• Management of heparin‑induced thrombocytopenia when alternative agents are not available.
• Use as a bridge therapy during transition to oral anticoagulants.

Adverse reactions to Heparina Sódica B Braun vary in frequency and severity; they are categorized as common or serious.

Common

• Minor bleeding at injection site.
• Small bruising or hematoma formation.
• Mild nausea or vomiting.
• Transient elevation of liver enzymes.

Serious

• Major hemorrhage requiring medical intervention.
• Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis.
• Allergic reactions such as urticaria or anaphylaxis.
• Spinal or epidural hematoma after neuraxial procedures.

Before prescribing Heparina Sódica B Braun, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Assess baseline coagulation parameters and platelet count.
• Adjust dose in patients with renal or hepatic impairment.
• Avoid use in active uncontrolled bleeding or recent intracranial hemorrhage.
• Use cautiously in pregnancy; benefits must outweigh risks.
• Monitor for signs of heparin‑induced thrombocytopenia during therapy.
• Discontinue before invasive procedures to reduce bleeding risk.

Heparina Sódica B Braun can interact with other medications, influencing anticoagulant effect or bleeding risk.

Avoid

• Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants).
• Combination with antiplatelet agents such as aspirin or clopidogrel.
• Concomitant administration of fibrinolytic drugs.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase bleeding.
• Certain antibiotics (e.g., quinolones) that can affect platelet function.
• High‑dose corticosteroids that may potentiate anticoagulation.